Debut Plus

BSE · 544312

Hamps Bio Limited

25.5
market cap
P/E
EPS
₹—
Book value
₹—
ROE
ROCE
Debt / equity
0.58

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

02.24.46.618.81Mar 22Mar 23Mar 24Mar 25Mar 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹9 Cr with net profit ₹-1 Cr — a -8.39% net margin, versus 4.37% the period before.

Shareholding

As of 2026-03-31

71.99%
promoter holding
  • Promoter71.99%
  • Public28.01%

395 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

100%71.99%Jul 24Mar 26

52-week position

Where the current price sits in its yearly band

13.3625.529.4

The band spans 2.2× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Trading · ranked #1 of 674 by market cap · medians across 50 industry peers

P/E
vs 37.61 peer med
P/B
vs 5.54 peer med
ROE %
vs 12.48 peer med
Margin %
vs 4.43 peer med
CompanyMkt capP/EP/BROEMargin
Adani Enterprises Limited₹4,16,478 Cr161.794.433.93%6.78%
Avenue Supermarts Limited₹2,40,679 Cr78.699.7812.14%4.29%
Trent Ltd.₹1,50,302 Cr82.221.324.62%8.64%
FSN E-Commerce Ventures Ltd.₹97,945 Cr367.6968.1813.87%2.41%
Vishal Mega Mart Limited₹48,441 Cr54.426.5211.32%6.61%
Aegis Logistics Limited₹45,897 Cr36.687.5714.83%13.95%
Aditya Infotech Limited₹45,298 Cr94.9224.1319.61%9.77%
Premier Energies Limited₹43,938 Cr26.3910.2235.05%19.67%
Redington Limited₹30,646 Cr17.043.0214.67%1.33%
Honasa Consumer Limited₹15,507 Cr61.4510.9714.16%9.75%
Hamps Bio Limited(this company)

AI analysis

AI-generated · google/gemini-2.5-flash

HAMPS Bio Limited is listed on the Indian markets. The company's 52-week high share price was Rs 35 and its 52-week low was Rs 13.36. The promoter holding stands at 71.99% as of March 31, 2026. The debt-to-equity ratio is 0.33.

Positives

  • +The promoter holding is high at 71.99% as of March 31, 2026, indicating significant insider confidence.
  • +Debt-to-equity ratio is 0.33, indicating a low level of financial leverage.
  • +Promoters have pledged 0% of their holdings, suggesting no current encumbrance on their shares.

Negatives

  • Net profit decreased by 40.60% from Rs 0.50 Cr in March 2024 to Rs 0.30 Cr in March 2025.
  • The company is under ESM 1 surveillance.
  • No quarterly results have been disclosed since March 2025.
  • The number of shareholders decreased from 589 in December 2024 to 395 in March 2026.

Financial performance

Revenue has shown growth over the past few years. It increased from Rs 5.34 Cr in March 2022 to Rs 6.82 Cr in March 2025. Net profit also increased from Rs 0.12 Cr in March 2022 to Rs 0.50 Cr in March 2024, before declining to Rs 0.30 Cr in March 2025.

Balance sheet

The company maintains a debt-to-equity ratio of 0.33. No other specific balance sheet figures or ratios such as market capitalization or book value were provided in the available data.

Ownership & pledges

Public shareholding is 28.01% for the same period. There are no shares pledged by the promoters. Institutional and FII holdings are 0%.

Regulatory & surveillance

The company is currently under ESM Stage 1 surveillance, which typically indicates enhanced monitoring by regulators due to certain parameters.

Data as of — price: 2026-09-11 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Hamps Bio Limitedshare price & fundamentals